Premium
Optimal blood stem cell mobilization using 10 μg/kg granulocyte colony‐stimulating factor (G‐CSF) alone for high‐dose melphalan intensification in multiple myeloma: An intrapatient controlled study
Author(s) -
Feremans W.,
Le Moine F.,
Ravoet C.,
Lambermont M.,
Bastin G.,
Delville J. P.,
Pradier O.,
Dupont E.,
Capel P.
Publication year - 1994
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830470214
Subject(s) - granulocyte colony stimulating factor , multiple myeloma , melphalan , medicine , mobilization , stem cell , granulocyte , oncology , chemotherapy , biology , genetics , archaeology , history
A recent randomized multicentric French study has shown that intensification with stem cell rescue improves the response rate and progression‐free survival in multiple myeloma. Transplantation with primed peripheral blood stem cells (PBSC) displays a faster hematological recovery, especially for platelets, as compared with a bone marrow stem cell graft. In multiple myeloma, the optimal mobilization method for PBSC is unknown. The present study compares mobilization with cyclophosphamide 4 g/m 2 + G‐CSF 5 μg/kg versus G‐CSF 5 μg/kg alone versus G‐CSF 10 μg/kg alone in two cases of multiple myeloma, using an intrapatient controlled evaluation of the amount of CD34‐positive cells obtained during each leukapheresis. In both cases, the highest CD34‐positive cells yield was obtained with G‐CSF at 10 μg/kg. Despite the low number of cases, this method, devoid of life‐threatening toxicity, might be of greatest interest in multiple myeloma. © 1994 Wiley‐Liss, Inc.